Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive


AAPS eChalk Talk: Three Strategies to Keep Your Program in Motion During the COVID-19 Pandemic

This event has passed. See all of our upcoming events, browse our Webinar Library for past presentations or, check out our Resource Library for blogs, case studies, news, toolkits and more. 

Join Nuventra on April 29 for an AAPS eChalk Talk discussing strategies to keep your program moving forward.

During these unprecedented times, it’s important to keep your drug development program moving toward approval. This session will highlight strategic actions to take right now to ensure that you minimize delays including:

  1. What to do in the interim if your study is on pause
  2. Considerations for planning and start-up of new studies
  3. What can you be doing now to minimize delays as backlogged studies initiate

Registration is free for AAPS members

Meet the Presenters

Mark A. Bush, Ph.D.
Dr. Bush has over 20 years of experience in clinical pharmacology and pharmacokinetics with a particular focus in clinical pharmacology study design and interpretation. His therapeutic concentrations include endocrinology and metabolism in early phases of development. Dr. Bush has worked on over 100 PK and population PK analyses.

Betty Hussey, Pharm.D.
Betty HusseyVice President, Clinical Pharmacology & Pharmacokinetics

Dr. Hussey has over 30 years of extensive leadership and experience in drug development, clinical development, clinical pharmacology, and pharmacokinetics across multiple therapeutic areas and all phases of development. Dr. Hussey’s primary therapeutic area experience includes dermatology, metabolic diseases, CNS, antivirals, anti-infectives with focus on early proof-of-concept.